Cargando…
Next-Generation Cancer Immunotherapy Targeting Glypican-3
Glypican-3 (GPC3), a 65 kD protein consisting of 580 amino acids, is a heparan sulfate proteoglycan bound to the cell membrane by glycosylphosphatidylinositol. This protein is expressed in the liver and the kidney of healthy fetuses but is hardly expressed in adults, except in the placenta. Contrari...
Autores principales: | Shimizu, Yasuhiro, Suzuki, Toshihiro, Yoshikawa, Toshiaki, Endo, Itaru, Nakatsura, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469401/ https://www.ncbi.nlm.nih.gov/pubmed/31024850 http://dx.doi.org/10.3389/fonc.2019.00248 |
Ejemplares similares
-
Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018) -
Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017) -
A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012) -
Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case
por: Sawada, Yu, et al.
Publicado: (2013) -
Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)